1. Johns Hopkins University & Medicine. Coronavirus resource center - Global Map 2022 [Available from: https://coronavirus.jhu.edu/map.html.
2. Bundesamt für Gesundheit BAG. Covid-19 Schweiz - Situationsbericht, Schweiz und Liechtenstein 2022 [updated May 24, 2022. Informationen zur aktuellen Lage, Stand 29. März 2022]. Available from: https://www.covid19.admin.ch/de/overview.
3. Global Health 50/50. The COVID-19 Sex-Disaggregated Data Tracker - Switzerland The Sex, Gender and COVID-19 Project2022 [updated 10/03/2022. Available from: https://globalhealth5050.org/the-sex-gender-and-covid-19-project/the-data-tracker/?explore=country&country=Switzerland#search.
4. Fernández-de-las-Peñas C, Martín-Guerrero JD, Pellicer-Valero ÓJ, Navarro-Pardo E, Gómez-Mayordomo V, Cuadrado ML, et al. Female Sex Is a Risk Factor Associated with Long-Term Post-COVID Related-Symptoms but Not with COVID-19 Symptoms: The LONG-COVID-EXP-CM Multicenter Study. Journal of Clinical Medicine. 2022;11(2):413.
5. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nature Medicine. 2021;27(4):626-31.
6. Gebhard CE, Sütsch C, Bengs S, Todorov A, Deforth M, Buehler KP, et al. Understanding the Impact of Sociocultural Gender on Post-acute Sequelae of COVID-19: a Bayesian Approach. medRxiv. 2022:2021.06.30.21259757.
7. Danielsen AC, Lee KMN, Boulicault M, Rushovich T, Gompers A, Tarrant A, et al. Sex disparities in COVID-19 outcomes in the United States: Quantifying and contextualizing variation. Social Science & Medicine. 2022;294:114716.
8. Shattuck-Heidorn H, Danielsen AC, Gompers A, Bruch JD, Zhao H, Boulicault M, et al. A finding of sex similarities rather than differences in COVID-19 outcomes. Nature. 2021;597(7877):E7-E9.
9. Johnson JL, Greaves L, Repta R. Better science with sex and gender: Facilitating the use of a sex and gender-based analysis in health research. Int J Equity Health. 2009;8:14.
10. Tadiri CP, Gisinger T, Kautzky-Willer A, Kublickiene K, Herrero MT, Raparelli V, et al. The influence of sex and gender domains on COVID-19 cases and mortality. Canadian Medical Association Journal. 2020;192(36):E1041-E5.
11. World Health Organization, Kari A. Gender and health 2022 [Available from: https://www.who.int/health-topics/gender#tab=tab_1.
12. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero JJ, DeMeo DL, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020;396(10250):565-82.
13. Gesensway D. Reasons for sex-specific and gender-specific study of health topics. Ann Intern Med. 2001;135(10):935-8.
14. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80.e8.
15. Qi J, Zhou Y, Hua J, Zhang L, Bian J, Liu B, et al. The scRNA-seq Expression Profiling of the Receptor ACE2 and the Cellular Protease TMPRSS2 Reveals Human Organs Susceptible to SARS-CoV-2 Infection. Int J Environ Res Public Health. 2021;18(1).
16. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology. 2004;203(2):631-7.
17. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2. American Journal of Respiratory and Critical Care Medicine. 2020;202(5):756-9.
18. Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79(23):14614-21.
19. Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH, 3rd, et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. 2020;182(2):429-46.e14.
20. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11(1):29.
21. Ferreira AJ, Santos RAS, Bradford CN, Mecca AP, Sumners C, Katovich MJ, et al. Therapeutic Implications of the Vasoprotective Axis of the Renin-Angiotensin System in Cardiovascular Diseases. Hypertension. 2010;55(2):207-13.
22. Crowley SD, Coffman TM. Recent advances involving the renin–angiotensin system. Experimental Cell Research. 2012;318(9):1049-56.
23. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J-C, Turner AJ, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System. Circulation Research. 2020;126(10):1456-74.
24. Qiao Y, Wang XM, Mannan R. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2. PNAS. 2021;118.
25. Samuel RM, Majd H, Richter MN, Ghazizadeh Z, Zekavat SM, Navickas A, et al. Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men. Cell Stem Cell. 2020;27(6):876-89.e12.
26. Baratchian M, McManus JM, Berk MP, Nakamura F, Mukhopadhyay S, Xu W, et al. Androgen regulation of pulmonary AR, TMPRSS2 and ACE2 with implications for sex-discordant COVID-19 outcomes. Scientific Reports. 2021;11(1):11130.
27. Chen J, Jiang Q, Xia X, Liu K, Yu Z, Tao W, et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell. 2020;19(7):e13168.
28. Bunyavanich S, Do A, Vicencio A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. Jama. 2020;323(23):2427-9.
29. Stelzig KE, Canepa-Escaro F, Schiliro M, Berdnikovs S, Prakash YS, Chiarella SE. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2020;318(6):L1280-l1.
30. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res. 2002;53(3):672-7.
31. Komukai K, Mochizuki S, Yoshimura M. Gender and the renin-angiotensin-aldosterone system. Fundam Clin Pharmacol. 2010;24(6):687-98.
32. Gupte M, Thatcher SE, Boustany-Kari CM, Shoemaker R, Yiannikouris F, Zhang X, et al. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. Arterioscler Thromb Vasc Biol. 2012;32(6):1392-9.
33. Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA, Diz DI. Update on the Angiotensin converting enzyme 2-Angiotensin (1-7)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol (Lausanne). 2014;4:201.
34. Lucas J, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discovery. 2014;4(11):1310-25.
35. Konrad H. Stopsack LAM, Emmanuel S. Antonarakis, Peter S. Nelson and Philip W. Kantoff. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer Discovery. 2020;10.
36. Muus C, Luecken MD, Eraslan G, Sikkema L, Waghray A, Heimberg G, et al. Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics. Nat Med. 2021;27(3):546-59.
37. Baughn LB, Sharma N, Elhaik E, Sekulic A, Bryce AH, Fonseca R. Targeting TMPRSS2 in SARS-CoV-2 Infection. Mayo Clin Proc. 2020;95(9):1989-99.
38. Okwan-Duodu D, Lim E-C, You S, Engman DM. TMPRSS2 activity may mediate sex differences in COVID-19 severity. Signal Transduction and Targeted Therapy. 2021;6(1):100.
39. Leach DA, Mohr A, Giotis ES, Cil E, Isac AM, Yates LL, et al. The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. Nature Communications. 2021;12(1):4068.
40. Li F, Han M, Dai P, Xu W, He J, Tao X, et al. Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nat Commun. 2021;12(1):866.
41. Welén K, Rosendal E, Gisslén M, Lenman A, Freyhult E, Fonseca-Rodríguez O, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81(3):285-93.
42. Lemes RMR, Costa AJ, Bartolomeo CS, Bassani TB, Nishino MS, Pereira G, et al. 17β-estradiol reduces SARS-CoV-2 infection in vitro. Physiol Rep. 2021;9(2):e14707.
43. Pivonello R, Auriemma RS, Pivonello C, Isidori AM, Corona G, Colao A, et al. Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger? Neuroendocrinology. 2021;111(11):1066-85.
44. Taneja V. Sex Hormones Determine Immune Response. Front Immunol. 2018;9:1931.
45. Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell. 2015;14(3):309-21.
46. Furman D, Hejblum BP, Simon N, Jojic V, Dekker CL, Thiébaut R, et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A. 2014;111(2):869-74.
47. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.
48. Jacobsen H, Klein SL. Sex Differences in Immunity to Viral Infections. Frontiers in Immunology. 2021;12.
49. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588(7837):315-20.
50. Jentsch-Ullrich K, Koenigsmann M, Mohren M, Franke A. Lymphocyte subsets' reference ranges in an age- and gender-balanced population of 100 healthy adults—A monocentric German study. Clinical Immunology. 2005;116(2):192-7.
51. Vural P, Akgul C, Canbaz M. Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women. Pharmacol Res. 2006;54(4):298-302.
52. Yasui T, Maegawa M, Tomita J, Miyatani Y, Yamada M, Uemura H, et al. Changes in serum cytokine concentrations during the menopausal transition. Maturitas. 2007;56(4):396-403.
53. Giglio T, Imro MA, Filaci G, Scudeletti M, Puppo F, De Cecco L, et al. Immune cell circulating subsets are affected by gonadal function. Life Sciences. 1994;54(18):1305-12.
54. Wambier CG, Vaño-Galván S, McCoy J, Gomez-Zubiaur A, Herrera S, Hermosa-Gelbard Á, et al. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign". J Am Acad Dermatol. 2020;83(2):680-2.
55. Lazzeri M, Duga S, Azzolini E, Fasulo V, Buffi N, Saita A, et al. Impact of chronic exposure to 5-alpha reductase inhibitors on the risk of hospitalization for COVID-19: a case-control study in male population from two COVID-19 regional centers of Lombardy, Italy. Minerva Urol Nephrol. 2022;74(1):77-84.
56. Cadegiani FA, McCoy J, Gustavo Wambier C, Goren A. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical). Cureus. 2021;13(2):e13047.
57. Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol. 2020;31(8):1040-5.
58. McCoy J, Goren A, Cadegiani FA, Vaño-Galván S, Kovacevic M, Situm M, et al. Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front Med (Lausanne). 2021;8:668698.
59. Yale K, Elsanadi R, Ghigi A, Zheng K, Goren A, Mesinkovska NA. Androgens and women: COVID-19 outcomes in women with acne vulgaris, polycystic ovarian syndrome, and hirsutism. Int J Dermatol. 2021;60(7):e267-e8.
60. Rambhatla A, Bronkema CJ, Corsi N, Keeley J, Sood A, Affas Z. COVID-19 Infection in Men on Testosterone Replacement Therapy. J Sex Med. 2020;18(1):215-8.
61. Rastrelli G, Di Stasi V, Inglese F, Beccaria M, Garuti M, Di Costanzo D, et al. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology. 2021;9(1):88-98.
62. Giagulli VA, Guastamacchia E, Magrone T, Jirillo E, Lisco G, De Pergola G, et al. Worse progression of COVID-19 in men: Is testosterone a key factor? Andrology. 2021;9(1):53-64.
63. Schroeder M, Schaumburg B, Mueller Z, Parplys A, Jarczak D, Roedl K, et al. High estradiol and low testosterone levels are associated with critical illness in male but not in female COVID-19 patients: a retrospective cohort study. Emerg Microbes Infect. 2021;10(1):1807-18.
64. Costeira R, Lee KA, Murray B, Christiansen C, Castillo-Fernandez J, Ni Lochlainn M, et al. Estrogen and COVID-19 symptoms: Associations in women from the COVID Symptom Study. PLoS One. 2021;16(9):e0257051.
65. Ding T, Zhang J, Wang T, Cui P, Chen Z, Jiang J, et al. Potential Influence of Menstrual Status and Sex Hormones on Female Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Cross-sectional Multicenter Study in Wuhan, China. Clin Infect Dis. 2021;72(9):e240-e8.
66. Montopoli M, Zorzi M, Cocetta V, Prayer-Galetti T, Guzzinati S, Bovo E, et al. Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy. Ann Oncol. 2021;32(5):676-7.
67. Seeland U, Coluzzi F, Simmaco M, Mura C, Bourne PE, Heiland M, et al. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC Med. 2020;18(1):369.
68. Shah SB. COVID-19 and Progesterone: Part 1. SARS-CoV-2, Progesterone and its potential clinical use. Endocr Metab Sci. 2021;5:100109.
69. Ghandehari S, Matusov Y, Pepkowitz S, Stein D, Kaderi T, Narayanan D, et al. Progesterone in Addition to Standard of Care vs Standard of Care Alone in the Treatment of Men Hospitalized With Moderate to Severe COVID-19: A Randomized, Controlled Pilot Trial. Chest. 2021;160(1):74-84.
70. Chen L, Li Q, Zheng D, Jiang H, Wei Y, Zou L, et al. Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China. N Engl J Med. 2020;382(25):e100.
71. Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and Estimated Population Burden of Selected Autoimmune Diseases in the United States. Clinical Immunology and Immunopathology. 1997;84(3):223-43.
72. Cook IF. Sexual dimorphism of humoral immunity with human vaccines. Vaccine. 2008;26(29):3551-5.
73. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. The Lancet Infectious Diseases. 2010;10(5):338-49.
74. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. New England Journal of Medicine. 2021;385(12):1078-90.
75. Bechmann N, Barthel A, Schedl A, Herzig S, Varga Z, Gebhard C, et al. Sexual dimorphism in COVID-19: potential clinical and public health implications. The Lancet Diabetes & Endocrinology. 2022;10(3):221-30.
76. Dagan N, Barda N, Balicer RD. Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex. New England Journal of Medicine. 2021;385(24):2299-.
77. Fairweather D, Cooper LT, Jr., Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol. 2013;38(1):7-46.
78. Male V. Menstrual changes after covid-19 vaccination. BMJ. 2021;374:n2211.
79. Bozkurt B, Kamat I, Hotez PJ. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144(6):471-84.
80. Power JR, Keyt LK, Adler ED. Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations. Expert Rev Cardiovasc Ther. 2022:1-11.
81. Block JP, Boehmer TK, Forrest CB, Carton TW, Lee GM, Ajani UA, et al. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(14):517-23.
82. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022;28(2):410-22.
83. Brady E, Nielsen MW, Andersen JP, Oertelt-Prigione S. Lack of consideration of sex and gender in COVID-19 clinical studies. Nature Communications. 2021;12(1):4015.
84. Heise L, Greene ME, Opper N, Stavropoulou M, Harper C, Nascimento M, et al. Gender inequality and restrictive gender norms: framing the challenges to health. Lancet. 2019;393(10189):2440-54.
85. Meleis AI, Caglia J, Langer A. Women and Health: Women's Dual Roles as Both Recipients and Providers of Healthcare. J Womens Health (Larchmt). 2016;25(4):329-31.
86. Oksuzyan A, Juel K, Vaupel JW, Christensen K. Men: good health and high mortality. Sex differences in health and aging. Aging Clin Exp Res. 2008;20(2):91-102.
87. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1789-858.
88. Bae S, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2021;107(5):373-80.
89. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020;5(7):831-40.
90. Moula AI, Micali LR, Matteucci F, Lucà F, Rao CM, Parise O, et al. Quantification of Death Risk in Relation to Sex, Pre-Existing Cardiovascular Diseases and Risk Factors in COVID-19 Patients: Let's Take Stock and See Where We Are. J Clin Med. 2020;9(9).
91. Global Health 50/50. Men, sex, gender and COVID-19 The Sex, Gender and COVID-19 Project2020 [Available from: https://globalhealth5050.org/the-sex-gender-and-covid-19-project/men-sex-gender-and-covid-19/.
92. The Lancet. The gendered dimensions of COVID-19. Lancet. 2020;395(10231):1168.
93. Anderson JL, Warren CA, Perez E, Louis RI, Phillips S, Wheeler J, et al. Gender and ethnic differences in hand hygiene practices among college students. Am J Infect Control. 2008;36(5):361-8.
94. Galasso V, Pons V, Profeta P, Becher M, Brouard S, Foucault M. Gender differences in COVID-19 attitudes and behavior: Panel evidence from eight countries. Proc Natl Acad Sci U S A. 2020;117(44):27285-91.
95. Wenham C, Smith J, Morgan R. COVID-19: the gendered impacts of the outbreak. Lancet. 2020;395(10227):846-8.
96. Godin M. As Cities Around the World Go on Lockdown, Victims of Domestic Violence Look for a Way Out. Time. 2020 March 18, 2020.
97. Frank E, Zhao Z, Fang Y, Rotenstein LS, Sen S, Guille C. Experiences of Work-Family Conflict and Mental Health Symptoms by Gender Among Physician Parents During the COVID-19 Pandemic. JAMA Netw Open. 2021;4(11):e2134315.
98. Familien in der Schweiz. Statistischer Bericht 2021: Bundesamt für Statistik (BFS); 2021. 100 p.
99. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. Bmj. 2021;374:n1648.
100. Ayoubkhani D, Munro M. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK : 7 April 2022 2022 [Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/7april2022.
101. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2021;397(10270):220-32.
102. Kozak R, Armstrong SM, Salvant E, Ritzker C, Feld J, Biondi MJ, et al. Recognition of Long-COVID-19 Patients in a Canadian Tertiary Hospital Setting: A Retrospective Analysis of Their Clinical and Laboratory Characteristics. Pathogens. 2021;10(10):1246.
103. Gonul M, Cemil B, Ayvaz H, Cankurtaran E, Ergin C, Gurel M. Comparison of quality of life in patients with androgenetic alopecia and alopecia areata*. Anais Brasileiros de Dermatologia. 2018;93(5):651-8.
104. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. Bmj. 2020;370:m3026.